Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) EBITDA (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed EBITDA for 16 consecutive years, with -$594147.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA rose 39.39% year-over-year to -$594147.0, compared with a TTM value of -$3.3 million through Sep 2025, up 27.27%, and an annual FY2024 reading of -$4.9 million, down 52.16% over the prior year.
  • EBITDA was -$594147.0 for Q3 2025 at China Pharma Holdings, down from -$508104.0 in the prior quarter.
  • Across five years, EBITDA topped out at -$270654.0 in Q1 2023 and bottomed at -$1.5 million in Q2 2022.
  • Average EBITDA over 5 years is -$952295.3, with a median of -$977467.0 recorded in 2024.
  • The sharpest move saw EBITDA tumbled 3502.33% in 2021, then surged 72.32% in 2023.
  • Year by year, EBITDA stood at -$836967.0 in 2021, then fell by 29.12% to -$1.1 million in 2022, then dropped by 2.37% to -$1.1 million in 2023, then decreased by 29.03% to -$1.4 million in 2024, then soared by 58.38% to -$594147.0 in 2025.
  • Business Quant data shows EBITDA for CPHI at -$594147.0 in Q3 2025, -$508104.0 in Q2 2025, and -$778056.0 in Q1 2025.